LeadXpro was founded in 2015 as a spin-out from the Paul Scherrer Institute (ETH) and is located between Zurich and Basel. The company aims to revolutionize the way drugs are being discovered for membrane proteins (e.g., GPCRs, ion channels, enzymes, transporters). These protein targets constitute more than half of the current drug targets but have not yet been fully amenable to structure-based drug design due to the considerable challenges in solving their atomic structures. To achieve our goal, we combine state-of-the-art methods for membrane protein science together with pioneering technologies in structural biology (Cryo-EM, XFEL). Our business model includes working in collaboration with Pharma/Biotech clients on their protein target of interest allowing them to keep their target exclusivity and all IP rights. We provide specialized expertise in areas such as construct design, protein generation, biophysical characterization of ligand interaction, crystallization, X-ray crystallography, electron microscopy and data analysis with computational methods. We also provide a lead discovery and optimization platform with the goal to deliver novel leads for challenging membrane protein targets. Find out more at www.leadxpro.com